A Phase 3 interventional study of Empasiprubart and IVIG (Intravenous Immunoglobulin) in Multifocal Motor Neuropathy (MMN) and MMN, sponsored by argenx. Active, not recruiting at 109 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by argenx · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months.
More information can be found here: https://clinicaltrials.argenx.com/empassion
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the double blinded - double dummy part A, participants receive empasiprubart and a placebo resembling the IVIg treatment in this arm
Biological: Empasiprubart · Other: IVIg-placebo
During the double blinded - double dummy part A, participants receive IVIg and a placebo resembling the empasiprubart treatment in this arm
Biological: IVIG (Intravenous Immunoglobulin) · Other: Empasiprubart-placebo
After completion of part A, participants can proceed to part B where they receive empasiprubart (no IVIg)
Biological: Empasiprubart
Intravenous infusion of empasiprubart
Intravenous infusion of IVIg
A placebo resembling the empasiprubart treatment
A placebo resembling the IVIg treatment
Change from baseline in grip strength (4-week average) in the most affected hand at week 24
Time frame: Up to 24 weeks
Change from baseline in MMN-RODS centile score at week 24
The 25-Item Rasch-Built Overall Disability Scale for MMN (MMN-RODS) is a questionnaire about the relationship between daily activities and the participants' health
Time frame: Up to 24 weeks
Change from baseline in mMRC-14 sum score
The modified Medical Research Council (mMRC)-14 is a questionnaire where each muscle group is scored from 0 (paralysis) to 5 (normal strength). A higher value indicates better muscle strength. The total score is based on the sum of both the left and right side of the body.
Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
PGI-C actual value
The Patient Global Impression of Change (PGI-C) is a 7-point scale depicting a participant's rating of overall improvement. The lower the score, the better the improvement.
Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
Change from baseline in CAP-PRI total score
The Chronic Acquired Polyneuropathy Patient-Reported Index (CAP-PRI) includes the assessment of 15 items. Items will be scored 0 (not at all), 1 (a little bit), or 2 (a lot), yielding a total score that ranges from 0 to 30.
Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
Percentage change from baseline in time to complete the 9-HPT with the dominant hand
The 9-Hole Peg Test (9-HPT) is a quantitative measure of upper extremity (arm and hand) function. Both the dominant and nondominant hands will be tested twice (2 consecutive trials of the dominant hand, followed immediately by 2 consecutive trials of the nondominant hand).
Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
Incidence of AEs, AESIs and SAEs
Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
Serum concentrations over time of empasiprubart
Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
Percent changes from baseline in free C2 and total C2 over time
Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
Incidence of anti-drug antibodies (ADA) against empasiprubart in serum
Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
Incidence of NAb against empasiprubart in serum
Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
Change from baseline in grip strength (3-day moving average) of the least affected hand over time
Time frame: Up to 24 weeks
AUC of change from baseline in grip strength (3-day moving average) for the most and least affected hands
Time frame: Up to 24 weeks
Percentage change from baseline in time to complete the 9-HPT with the nondominant hand over time
The 9-Hole Peg Test (9-HPT) is a quantitative measure of upper extremity (arm and hand) function. Both the dominant and nondominant hands will be tested twice (2 consecutive trials of the dominant hand, followed immediately by 2 consecutive trials of the nondominant hand).
Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
Change from baseline in sum scores for mMRC-10 and mMRC-14 restricted to the 2 most affected muscle groups over time
The modified Medical Research Council (mMRC) is a questionnaire where each muscle group is scored from 0 (paralysis) to 5 (normal strength). A higher value indicates better muscle strength. The total score is based on the sum of both the left and right side of the body.
Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
Proportion of participants and shift from baseline over time by level of severity on PGI-S
Patient Global Impression of Severity (PGIS) is a 7-point scale depicting a participant's rating of overall illness severity. Higher scores mean a higher severity.
Time frame: Up to 24 weeks
Change from baseline in Rasch-Transformed Fatigue Severity Scale (RT-FSS) score over time
Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
Change from baseline in physical component and mental component scores of 12-Item Short Form Survey (SF-12) over time
Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
Proportion of participants and shift from baseline by each dimension of the EQ-5D-5L scale
Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
Changes from baseline in MMN-RODS centile score
The 25-Item Rasch-Built Overall Disability Scale for MMN (MMN-RODS) is a questionnaire about the relationship between daily activities and the participants' health
Time frame: Up to 120 weeks (part B)
Changes from baseline in grip strength (3-day moving average; both hands)
Time frame: Up to 120 weeks (part B)
Actual values of PGI-S over time
Patient Global Impression of Severity (PGIS) is a 7-point scale depicting a participant's rating of overall illness severity. Higher scores mean a higher severity.
Time frame: Up to 120 weeks (part B)
Change from baseline in grip strength (3-day moving average) in the most affected hand at week 24
Time frame: Up to 24 weeks
Showing the first 100 of 109 sites across 26 countries. Choose a country and city above to see the rest.
Plan to share: No
Started Dec 2024 (actual). Primary completion is estimated for Sep 2026, 21 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empasiprubart